Who Owns Hisun Pharmaceutical Company?

Who Owns Hisun Pharmaceutical Company?

Understanding the ownership of a major pharmaceutical firm like Zhejiang Hisun Pharmaceutical Co., Ltd. is key to grasping its strategic path and influence. Established in 1956, Hisun Pharmaceutical is a prominent Chinese pharmaceutical company based in Taizhou.

The company has grown from its chemical roots into a full-spectrum pharmaceutical entity, involved in R&D, manufacturing, and sales of APIs and finished products. Its diverse offerings span anti-infectives, oncology, and cardiovascular treatments, serving both domestic and international markets.

As of 2021, Hisun Pharmaceutical was a significant player, recognized as one of China's largest producers of antibiotics and anti-tumor drugs. The company's financial standing in 2021 included total assets of 20 billion yuan and sales exceeding 10 billion yuan RMB. By July 24, 2025, its market capitalization reached $2 billion, with 1.2 billion shares outstanding, reflecting its substantial market presence.

Exploring Hisun Pharmaceutical's ownership reveals its journey from initial stakes to its current major shareholders, including institutional investors and state-backed entities. This structure significantly influences its operational strategies and corporate governance, impacting areas such as its Hisun Pharmaceutical BCG Matrix.

Zhejiang Hisun Pharmaceutical Co., Ltd. was established in 1956, initially as a chemical enterprise before shifting its focus to pharmaceuticals in the early 1970s. While precise details on the initial founders, their backgrounds, and exact equity distribution are not widely publicized, the company's trajectory points towards state ownership during its formative years.

Company Origins

Hisun Pharmaceutical began its journey in 1956 as a chemical enterprise. It later transitioned into the pharmaceutical sector in the early 1970s.

Early Ownership Structure

Given its state-owned status upon public listing, it's highly probable that early ownership was primarily vested with the state.

Public Listing Milestone

A significant shift in Hisun Pharmaceutical's ownership occurred in 2000. The company issued A-shares and became a state-owned listed entity.

Founding Vision Alignment

The founding team's vision and control distribution were likely aligned with state objectives during the company's early development.

Limited Early Investor Data

Information regarding early backers, angel investors, or initial ownership disputes is not specified in available records.

Transition to Public Market

The company's entry into the stock market in 2000 marked a key moment in its corporate history and ownership evolution.

The company's history indicates a transition from a chemical base to pharmaceuticals, with its public listing in 2000 as a state-owned enterprise marking a pivotal moment in its ownership structure. This transition suggests a shift towards a more formalized corporate governance, aligning with the Growth Strategy of Hisun Pharmaceutical as it entered the public market.

Key Ownership Developments

Hisun Pharmaceutical's ownership structure has evolved significantly since its inception. The company's state-owned status at the time of its public listing in 2000 is a critical factor in understanding its early corporate control.

• Established in 1956 as a chemical enterprise.
• Transitioned to pharmaceuticals in the early 1970s.
• Became a state-owned listed company in 2000 upon issuing A-shares.
• Early ownership likely concentrated within state entities.
• Details on initial private investors or founder equity splits are not readily available.

Complete Hisun Pharmaceutical Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Zhejiang Hisun Pharmaceutical Co., Ltd. became a publicly traded entity in 2000 with its A-share listing. This move marked a significant shift in its ownership structure, opening the door for broader investment and public scrutiny. The company's journey since then reflects a dynamic interplay between state-backed interests and the growing influence of institutional capital.

The current ownership landscape of Hisun Pharmaceutical is characterized by a substantial presence of state-affiliated entities, underscoring a strategic alignment with national development objectives. Zhejiang Haizheng Group Co., Ltd. stands as the largest shareholder, holding 27.45% of the company's shares. This significant stake, coupled with holdings from other state-owned groups like Zhejiang International Business Group Co., Ltd. (6.22%) and Taizhou Jiaojiang State Owned Capital Operation Group Co., Ltd. (5.13%), indicates a strong governmental influence on the company's strategic direction and corporate governance. These state-linked entities collectively manage a considerable portion of Hisun Pharmaceutical's equity, suggesting a commitment to fostering the growth of the domestic pharmaceutical sector. The presence of institutional investors, such as The Vanguard Group, Inc. (0.33%) and Dimensional Fund Advisors LP (0.19%), along with 18 other entities that have filed with the SEC, demonstrates a degree of market confidence. However, their combined holdings are considerably smaller than those of the primary state-owned shareholders, reinforcing the dominant role of state-affiliated capital in the company's structure. Understanding these ownership dynamics is crucial for grasping the company's operational framework and its adherence to Mission, Vision & Core Values of Hisun Pharmaceutical.

Key Ownership Insights

Hisun Pharmaceutical's ownership is a blend of state-backed entities and institutional investors, with state-affiliated groups holding the majority of shares.

• Zhejiang Haizheng Group Co., Ltd. is the largest shareholder with 27.45%.
• State-owned entities collectively exert significant influence.
• Institutional investors like Vanguard and Dimensional Fund Advisors also hold stakes.
• The company's market capitalization was $2 billion as of July 24, 2025, with 1.2 billion shares outstanding.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Zhejiang Hisun Pharmaceutical Co., Ltd.'s Board of Directors is currently led by Mr. Weihong Xiao, who holds the positions of Chief Executive Officer and Chairman of the Board as of October 10, 2024. The board's composition reflects an integrated leadership, with key executives also serving as directors, ensuring direct management involvement in strategic oversight.

The board of directors at Hisun Pharmaceutical demonstrates considerable experience, with an average tenure of 6.2 years and an average age of 46.5 years among its members. While the specific voting power structure is not detailed, the substantial ownership by state-affiliated entities, such as Zhejiang Haizheng Group Co., Ltd. holding 27.45% as of December 30, 2024, indicates a significant influence on voting outcomes. There have been no reported governance controversies or activist campaigns affecting the company's control.

Understanding Hisun Pharmaceutical's Corporate Control

The ownership structure of Hisun Pharmaceutical is a key factor in understanding its corporate control. The significant stake held by Zhejiang Haizheng Group Co., Ltd. suggests a strong alignment with state interests, which can influence strategic decisions and long-term direction.

• Major shareholders like Zhejiang Haizheng Group Co., Ltd. wield considerable voting power.
• The integrated leadership structure places key executives in directorial roles.
• Understanding the Revenue Streams & Business Model of Hisun Pharmaceutical provides context for board decisions.
• The company's governance is influenced by its substantial state-affiliated ownership.

Hisun Pharmaceutical Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Zhejiang Hisun Pharmaceutical Co., Ltd. has demonstrated a focus on shareholder value and strategic expansion over the last 3-5 years. The company's recent financial activities, including significant dividend payouts and share repurchases, highlight its commitment to its investors and its evolving corporate control dynamics.

The company's financial performance saw a notable recovery in 2024, with a substantial increase in net income compared to the previous year. This turnaround, coupled with strategic R&D investments and international market expansion, positions the company for continued development. The increasing institutional ownership further suggests a broadening base of stakeholders in the Hisun Pharmaceutical company structure.

Shareholder Returns

In 2024, Hisun Pharmaceutical planned a cash dividend of 2.10 yuan per 10 shares. The company also executed a share repurchase program totaling 96.46 million yuan in 2024.

Financial Turnaround

After a net loss in 2023, Hisun Pharmaceutical reported a net income of 601.18 million CNY in 2024. Revenue for 2024 was 9.79 billion CNY, exceeding analyst estimates.

Strategic Growth Initiatives

Hisun Pharmaceutical is actively developing innovative drugs and expanding its global market presence. The company's products reach over 70 countries, with 80% of API income generated from overseas markets.

Ownership Trends

As of May 30, 2025, 18 institutional owners held a total of 3,725,564 shares. This indicates a growing institutional interest in Hisun Pharmaceutical ownership. Understanding the Marketing Strategy of Hisun Pharmaceutical can provide further context on its market positioning and investor appeal.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE